hans
Recent DNLI News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/15/2024 08:10:01 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/15/2024 08:09:18 PM
- Denali Therapeutics Announces Publication in Science Translational Medicine Demonstrating the Potential of the Oligonucleotide Transport Vehicle Platform to Achieve Broad Biodistribution of Antisense Oligonucleotides in the CNS and Muscle Following Intrave • GlobeNewswire Inc. • 08/14/2024 06:00:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/14/2024 12:37:32 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/01/2024 10:52:37 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2024 10:48:19 AM
- Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights • GlobeNewswire Inc. • 08/01/2024 10:45:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/11/2024 12:06:11 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/06/2024 08:26:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/04/2024 10:32:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/04/2024 10:30:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/04/2024 10:27:58 PM
- Denali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease Therapies • GlobeNewswire Inc. • 06/03/2024 12:00:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/31/2024 08:01:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 08:03:33 PM
- Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights • GlobeNewswire Inc. • 05/07/2024 08:01:00 PM
- Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial • GlobeNewswire Inc. • 05/01/2024 12:00:00 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 03/01/2024 09:51:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2024 01:07:37 PM
- Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights • GlobeNewswire Inc. • 02/27/2024 01:05:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2024 01:03:38 PM
- Denali Therapeutics Announces $500 million Private Placement Equity Financing • GlobeNewswire Inc. • 02/27/2024 01:00:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 01:02:47 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/16/2024 02:15:20 AM
HealthLynked Corp. Announces Second Quarter and First Half 2024 Results: Continued Cost Reductions Set the Stage for Strategic Shift to App-Based Technology Services • HLYK • Aug 16, 2024 8:00 AM
PickleJar Announces Official Name Change and New Ticker Symbol • NREG • Aug 15, 2024 2:23 PM
VAYK's Q2 Profit Added to Accumulated Net Profit of Over $2.2 Million In 18 Months • VAYK • Aug 15, 2024 9:07 AM
Swifty Global Reports Strong Q2 Performance and Prepares for Major Exchange Uplisting • DRCR • Aug 15, 2024 9:04 AM
Mayback's Global Entertainment Signs Global Distribution Agreement with Children's Media Studio • AHRO • Aug 15, 2024 8:45 AM
POET Technologies Reports Second Quarter 2024 Financial Results • POET • Aug 15, 2024 8:04 AM